Is there a role for PSMA PET/CT in oligometatastic RCC?
Check out our @JournalofNucMed PEDESTAL study on PSMA-guided metastasis-directed therapy from @PeterMacCC@_ShankarSiva@DrMHofman
🧍33 pts & 60 metastases
🛜 93% radiotherapy
📖Median follow-up> 4y
✅Local control: 94% at 1y, 85% at 3y
✅Freedom from change (or commencement) of systemic therapy: 76% at 1y, 65% at 3y
... how common is PSMA-negative significant prostate
cancer? In the proPSMA study it was 3.3%
Hot of the press in @JournalofNucMed: https://t.co/S6phT0F03X
Wonderful work from @davcmed and team @pros_tic including @ButeauJames@declangmurphy
10 BECAS DE INSCRIPCIÓN PARA EL UROTERAGLATAM 2025
“Asiste al evento Uro-Teragnóstico multidisciplinario más grande de Latinoamérica”
INSCRIPCIONES : https://t.co/YkH5biZkb2
CANCÚN CENTER – MÉXICO 11 Y 12 MARZO
BECAS : https://t.co/63WabfcjMD
One year ago we published the @ANZUPtrials#TheraP follow-up... the Appendix contains the answers to many questions I am often asked. Three of my favourite Figures below:
1) Survival in patients who had FDG-discordant or low PSMA-expression and were not randomised vs. LuPSMA/cabazitaxel
2) Survival by PSA response. PSA≥90 had a hazard ratio of 0.34 !!
3) Prognostic power of FDG PET/CT (metabolic tumour volume) for survival - the single most powerful parameter
https://t.co/Ofl4B63opp
@MovemberAUS@PCF_Science
🗞️ News! Asiste al evento Uro-Teragnóstico Multidisciplinario más grande de LATAM.
11 y 12 de marzo - Cancún 🇲🇽
🔥 40% de descuento para ex alumnos/as de nuestro curso o quienes se han inscripto este año. Solicita tu código.
Reserva tu lugar! 👉 https://t.co/PXI0EFscyN
Andrei Iagaru highlighting the relative cost of FDG, PSMA and Pluvicto. $2500 can $6500 vs $300,000 ! "I'm not a health economist but it seems FDG may be cost effective" #FelixFeng symposium @ASCO#GU25
Lead-212 (²¹²Pb) DOTAMTATE could potentially offer a more effective targeted α-therapy treatment option for SSTR2-positive neuroendocrine tumours
https://t.co/y5ocR7UqAY
SPECT deserves RESPECT!
@drlouiseemmett makes the argument that it is a powerful tool for theranostics ➤ enabling early, personalised treatment response evaluation ➤ optimizes outcomes by guiding therapy adjustments.
✓practical advantages over serial PET.
https://t.co/LLLOEVoDLh
@JournalofNucMed
It's been a busy 2024 @pros_tic with clinical trials, discovery research & education all progressing at pace
We've put together a podcast of highlights:
https://t.co/lu4uMgcuDT
@PCF_Science
ICPO Foundation and Prof. Richart P. Baum (@baumrp) applauds new radiotherapy and theranostics report of the Lancet Oncology Commission. Three ICPO SAB members @DrMHofman Michael Hofman, Mike Sathekge and Andrew Scott participated in the report.
MIM Software tiene el gusto de ser uno de los patrocinadores de esta serie educativa que exhibe las últimas inovaciones en #teragnóstico. Sintonice cada miércoles y aprenda más sobre PSMA, dosimetría en teranóstico y más. https://t.co/vrHxwktPNG